Assembly Bio Narrows Q2 Loss to $28.7M Amid R&D Streamlining

Ticker: ASMB · Form: 10-Q · Filed: 2025-08-06T00:00:00.000Z

Sentiment: mixed

Topics: Biotechnology, Pharmaceuticals, Antiviral Drugs, HBV, HSV, Clinical Stage, Gilead Collaboration

Related Tickers: ASMB, GILD

TL;DR

ASMB is burning less cash and maintaining its Gilead partnership, but still deep in the red – a speculative bet on pipeline success.

AI Summary

ASSEMBLY BIOSCIENCES, INC. reported a net loss of $28.7 million for the three months ended June 30, 2025, a decrease from the $30.1 million net loss for the same period in 2024. Revenue from the Gilead Sciences, Inc. collaboration was $10.0 million for the six months ended June 30, 2025, compared to $10.0 million for the six months ended June 30, 2024. Research and development expenses decreased to $20.0 million for the three months ended June 30, 2025, from $22.5 million in the prior year, reflecting a strategic focus on specific programs. General and administrative expenses remained relatively stable at $8.0 million for the three months ended June 30, 2025, compared to $7.6 million in 2024. The company's cash and cash equivalents stood at $100.0 million as of June 30, 2025, down from $120.0 million at December 31, 2024. The company continues to advance its HBV and HSV programs, with ABI-1179 being a key focus. The strategic outlook emphasizes continued development of its antiviral pipeline, supported by the ongoing collaboration with Gilead Sciences, Inc.

Why It Matters

For investors, the narrowing net loss to $28.7 million, coupled with stable collaboration revenue from Gilead Sciences, Inc., suggests a more controlled burn rate, which is crucial for a clinical-stage biotech. Employees might see this as a sign of program stability and continued investment in key pipeline assets like ABI-1179. Customers, particularly future patients, could benefit from the continued advancement of HBV and HSV therapies. In a competitive landscape, efficient R&D spending, as evidenced by the $2.5 million reduction in R&D expenses, is vital for ASMB to sustain its drug development efforts against larger pharmaceutical rivals.

Risk Assessment

Risk Level: high — The company reported a net loss of $28.7 million for Q2 2025 and holds $100.0 million in cash and cash equivalents, down from $120.0 million at year-end 2024. This burn rate, coupled with reliance on a single major collaboration with Gilead Sciences, Inc. for revenue, indicates significant financial risk and dependence on successful clinical outcomes.

Analyst Insight

Investors should monitor ASMB's cash burn rate and the progress of its clinical trials, particularly ABI-1179. Given the high risk, consider a small, speculative position only if you have a high tolerance for risk and believe in the long-term potential of their antiviral pipeline.

Financial Highlights

debt To Equity: N/A
revenue: $10.0M
operating Margin: N/A
total Assets: N/A
total Debt: N/A
net Income: -$28.7M
eps: N/A
gross Margin: N/A
cash Position: $100.0M
revenue Growth: 0.0%

Revenue Breakdown

Segment	Revenue	Growth
Gilead Sciences, Inc. Collaboration	$10.0M	0.0%

Key Numbers

$28.7M — Net Loss (Decreased from $30.1M in Q2 2024, indicating improved financial management.)
$10.0M — Collaboration Revenue (Stable for H1 2025 and H1 2024, highlighting consistent partnership with Gilead Sciences, Inc.)
$20.0M — R&D Expenses (Reduced from $22.5M in Q2 2024, reflecting strategic focus and cost control.)
$100.0M — Cash & Equivalents (Decreased from $120.0M at year-end 2024, indicating ongoing cash burn.)
ABI-1179 — Key Pipeline Asset (A primary focus in the company's HBV and HSV programs.)

Key Players & Entities

ASSEMBLY BIOSCIENCES, INC. (company) — filer of the 10-Q
Gilead Sciences, Inc. (company) — collaboration partner and revenue source
$28.7 million (dollar_amount) — net loss for Q2 2025
$30.1 million (dollar_amount) — net loss for Q2 2024
$10.0 million (dollar_amount) — revenue from Gilead collaboration for H1 2025 and H1 2024
$20.0 million (dollar_amount) — research and development expenses for Q2 2025
$22.5 million (dollar_amount) — research and development expenses for Q2 2024
$8.0 million (dollar_amount) — general and administrative expenses for Q2 2025
$7.6 million (dollar_amount) — general and administrative expenses for Q2 2024
$100.0 million (dollar_amount) — cash and cash equivalents as of June 30, 2025

FAQ

What was ASSEMBLY BIOSCIENCES, INC.'s net loss for the second quarter of 2025?

ASSEMBLY BIOSCIENCES, INC. reported a net loss of $28.7 million for the three months ended June 30, 2025, which is an improvement from the $30.1 million net loss in the same period of 2024.

How much revenue did ASSEMBLY BIOSCIENCES, INC. generate from its collaboration with Gilead Sciences, Inc.?

The company generated $10.0 million in revenue from its collaboration with Gilead Sciences, Inc. for the six months ended June 30, 2025, consistent with the $10.0 million reported for the same period in 2024.

What were ASSEMBLY BIOSCIENCES, INC.'s research and development expenses in Q2 2025?

Research and development expenses for ASSEMBLY BIOSCIENCES, INC. were $20.0 million for the three months ended June 30, 2025, a decrease from $22.5 million in the corresponding period of 2024.

What is the current cash position of ASSEMBLY BIOSCIENCES, INC.?

As of June 30, 2025, ASSEMBLY BIOSCIENCES, INC. held $100.0 million in cash and cash equivalents, a reduction from $120.0 million at December 31, 2024.

What are the key pipeline programs for ASSEMBLY BIOSCIENCES, INC.?

ASSEMBLY BIOSCIENCES, INC. is primarily focused on advancing its HBV and HSV programs, with ABI-1179 identified as a key asset within these development efforts.

How has ASSEMBLY BIOSCIENCES, INC. managed its general and administrative expenses?

General and administrative expenses for ASSEMBLY BIOSCIENCES, INC. remained relatively stable at $8.0 million for the three months ended June 30, 2025, compared to $7.6 million in the prior year period.

What is the strategic outlook for ASSEMBLY BIOSCIENCES, INC.?

The strategic outlook for ASSEMBLY BIOSCIENCES, INC. emphasizes the continued development of its antiviral pipeline, supported by the ongoing collaboration with Gilead Sciences, Inc., aiming for further clinical progress.

What are the main risks for investors in ASSEMBLY BIOSCIENCES, INC.?

Investors face risks due to the company's ongoing net losses, significant cash burn, and reliance on the success of its clinical-stage pipeline and the single major collaboration with Gilead Sciences, Inc.

Has ASSEMBLY BIOSCIENCES, INC. issued any new shares recently?

The filing mentions 'TwoThousandAndTwentyFourAtTheMarketOfferings' and 'JuneSixteenTwoZeroTwoFourWarrants', indicating potential equity activities, but specific share issuance numbers for the current period are not detailed in the summary.

What does the decrease in R&D expenses mean for ASSEMBLY BIOSCIENCES, INC.?

The decrease in R&D expenses to $20.0 million suggests that ASSEMBLY BIOSCIENCES, INC. is strategically streamlining its research efforts, potentially focusing resources on its most promising programs like ABI-1179 to optimize spending.

Risk Factors

Ongoing Cash Burn [medium — financial]: The company's cash and cash equivalents decreased from $120.0 million at December 31, 2024, to $100.0 million as of June 30, 2025. This $20.0 million reduction highlights the ongoing operational cash burn, which requires careful management and potential future financing.
Dependence on Key Programs [high — operational]: Assembly Biosciences' strategic outlook heavily relies on the continued development of its HBV and HSV programs, with ABI-1179 being a key focus. Any setbacks or delays in these specific programs could significantly impact the company's future prospects.
Drug Development Regulatory Hurdles [high — regulatory]: As a biotechnology company, Assembly Biosciences faces inherent risks associated with the lengthy and complex regulatory approval process for new drugs. Failure to meet regulatory standards for its HBV and HSV programs could lead to significant delays or outright rejection.
Competitive Landscape [medium — market]: The pharmaceutical and biotechnology sectors are highly competitive. Assembly Biosciences must contend with established players and emerging companies developing treatments for similar indications, such as Hepatitis B Virus (HBV) and Herpes Simplex Virus (HSV).

Industry Context

The biotechnology sector, particularly in areas like antiviral therapies for HBV and HSV, is characterized by high R&D investment, long development cycles, and significant regulatory hurdles. Companies often rely on strategic partnerships and collaborations to fund development and share risk. The competitive landscape is intense, with both large pharmaceutical companies and smaller biotechs vying for market share and therapeutic breakthroughs.

Regulatory Implications

Assembly Biosciences operates within a highly regulated industry. The success of its drug candidates, such as ABI-1179, is contingent upon navigating the rigorous approval processes of regulatory bodies like the FDA. Any delays or failures in clinical trials or regulatory submissions could have severe financial and strategic consequences.

What Investors Should Do

[object Object]
[object Object]
[object Object]

Key Dates

2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q, showing a net loss of $28.7 million and cash reserves of $100.0 million.
2025-08-06: 10-Q Filing Date — The company officially filed its quarterly report, providing detailed financial and operational information to the public.
2024-06-30: End of Second Quarter 2024 — Comparative period for Q2 2025 results, showing a net loss of $30.1 million and R&D expenses of $22.5 million.
2024-12-31: End of Fiscal Year 2024 — Previous reporting period for cash and cash equivalents, which stood at $120.0 million.

Glossary

10-Q: A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document is the primary source of the financial and operational data analyzed.)
Collaboration Revenue: Revenue generated from agreements with other companies, such as licensing or co-development deals. (Represents a key revenue stream for Assembly Biosciences, particularly from its partnership with Gilead Sciences, Inc.)
Research and Development (R&D) Expenses: Costs incurred by a company in the process of developing new products or services, including scientific research and experimentation. (A significant expense category for Assembly Biosciences, reflecting its investment in pipeline development.)
Cash and Cash Equivalents: Highly liquid short-term investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. (Indicates the company's immediate liquidity and its ability to fund ongoing operations.)
Net Loss: The total expenses of a company exceed its total revenues over a specific period. (Assembly Biosciences is currently operating at a net loss, a common characteristic of early-stage biotechnology companies.)
ABI-1179: A specific drug candidate being developed by Assembly Biosciences, likely for the treatment of HBV or HSV. (Identified as a key focus for the company's development pipeline.)

Year-Over-Year Comparison

Compared to the prior year's second quarter, Assembly Biosciences has managed to reduce its net loss from $30.1 million to $28.7 million, indicating some improvement in financial management. Research and development expenses also saw a decrease from $22.5 million to $20.0 million, reflecting a strategic focus. However, the company's cash position has declined by $20.0 million from the end of 2024 to $100.0 million as of June 30, 2025, highlighting continued cash burn.

From the Filing

0000950170-25-104060.txt : 20250806 0000950170-25-104060.hdr.sgml : 20250806 20250806161602 ACCESSION NUMBER: 0000950170-25-104060 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 56 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250806 DATE AS OF CHANGE: 20250806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASSEMBLY BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001426800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35005 FILM NUMBER: 251189799 BUSINESS ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (833) 409-4583 MAIL ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: VENTRUS BIOSCIENCES INC DATE OF NAME CHANGE: 20080211 10-Q 1 asmb-20250630.htm 10-Q 10-Q false Q2 0001426800 --12-31 http://fasb.org/us-gaap/2025#CashEquivalentsMember http://fasb.org/us-gaap/2025#CashEquivalentsMember http://fasb.org/us-gaap/2025#CashEquivalentsMember http://fasb.org/us-gaap/2025#CashEquivalentsMember http://fasb.org/us-gaap/2025#CashEquivalentsMember http://fasb.org/us-gaap/2025#CashEquivalentsMember http://fasb.org/us-gaap/2025#CashEquivalentsMember http://fasb.org/us-gaap/2025#CashEquivalentsMember 1 http://fasb.org/srt/2025#ChiefExecutiveOfficerMember 0001426800 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001426800 us-gaap:CommercialPaperMember 2025-06-30 0001426800 us-gaap:MoneyMarketFundsMember us-gaap:CashEquivalentsMember 2025-06-30 0001426800 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-06-30 0001426800 us-gaap:RetainedEarningsMember 2024-12-31 0001426800 asmb:GileadSciencesIncorporatedMember asmb:OptionLicenseAndCollaborationAgreementMember 2024-01-01 2024-06-30 0001426800 us-gaap:RelatedPartyMember 2025-01-01 2025-06-30 0001426800 us-gaap:CommonStockMember 2024-06-30 0001426800 asmb:JuneSixteenTwoZeroTwoFourWarrantsMember 2025-06-30 0001426800 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2025-06-30 0001426800 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001426800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001426800 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001426800 asmb:ABIOneOneSevenNineMember 2024-04-01 2024-06-30 0001426800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001426800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001426800 us-gaap:MoneyMarketFundsMember us-gaap:CashEquivalentsMember 2024-12-31 0001426800 asmb:TwoThousandAndTwentyFourAtTheMarketOfferingsMember 2025-06-30 0001426800 us-gaap:CommonStockMember asmb:GileadSciencesIncorporatedMember asmb:OptionLicenseAndCollaborationAgreementMember 2025-01-01 2025-06-30 0001426800 us-gaap:CommonStockMember asmb:GileadSciencesIncorporatedMember asmb:OptionLicenseAndCollaborationAgreementMember 2023-10-01 2023-10-31 0001426800 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001426800 us-gaap:CommercialPaperMember 2024-12-31 0001426800 us-gaap:CommonStockMember asmb:GileadSciencesIncorporatedMember asmb:EquityAgreementsMember 2023-10-01 2023-10-31 0001426800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001426800 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001426800 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001426800 2024-12-31 0001426800 asmb:JuneSeventeenTwoZeroTwoFourWarrantsMember 2024-12-31 0001426800 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-g